How do we separate proven findings from marketing hype?
Hypertension is one of the best-studied conditions on earth — and the evidence here teaches the sharpest lesson in supplement literacy: small effects can be real and still be outclassed. We interpret the literature in the context of the 2017 ACC/AHA guideline and the 2018 ESC/ESH recommendations.
Blood pressure research rewards understanding what millimeters actually buy:
Scipione Riva-Rocci develops the sphygmomanometer — blood pressure becomes measurable at the bedside for the first time.
Nikolai Korotkoff describes the sounds that let the cuff measure systolic and diastolic pressure — the technique in every clinic today.
The Framingham Heart Study enrolls a town and follows it for life — inventing the risk-factor model and proving hypertension predicts strokes and heart attacks.
The first randomized trial shows treating severe hypertension prevents strokes and heart failure — 'silent killer' meets its match.
A purpose-engineered diet lowers systolic pressure ~11 mmHg in hypertensive adults — food, validated at the scale of a medication.
ACC/AHA lowers the hypertension threshold to 130/80 based on lifetime risk — tens of millions reclassified overnight, prevention moved earlier.
POPULATION · 459 adults, ~27% with hypertension
FINDING · The DASH diet lowered systolic blood pressure by 5.5 mmHg overall and about 11 mmHg in hypertensive participants, within 8 weeks — without sodium restriction or weight loss.
LIMITATION · Controlled feeding study: all food provided, 8-week duration; real-world self-prepared versions show smaller effects.
POPULATION · 412 adults across diet and sodium levels
FINDING · Every step down in sodium lowered blood pressure at every diet level; the lowest-sodium DASH combination produced the largest reductions.
LIMITATION · Feeding-study design and short duration; long-term adherence and outcomes inferred, not measured.
POPULATION · 9,361 adults at elevated cardiovascular risk
FINDING · Targeting systolic pressure below 120 (versus below 140) reduced major cardiovascular events by about 25% — proof that lower targets translate to fewer events.
LIMITATION · Intensive arm had more adverse events (hypotension, electrolyte and kidney changes); medication-based, carefully monitored — not a lifestyle or supplement result.